A wireless, insertable pressure sensor to assist in the diagnosis of urinary incontinence and other bladder disorders is safe, feasible and well-tolerated in women with refractory overactive bladder.
Researchers at Cleveland Clinic are in search of the biological reason behind why men are more likely than women to develop COVID-19 and typically have more severe disease.
Higher NAb levels provided protection against illness and transmission in study models.
New findings from a Cleveland Clinic-led study upend conventional wisdom about the long-term outcomes of ACL surgery.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
What do the phase 3 trials of COVID-19 vaccine candidates mean for the general population and healthcare workers battling the virus on the frontlines? In this article, immunologist Thaddeus Stappenbeck, MD, PhD, puts the trial results into context.
A potential novel therapeutic strategy in rhabdomyosarcoma, a new study finds. In this article, Neetu Gupta, PhD, director of the Center of Excellence in Lymphoid Malignancies Research explains her findings.
A new network medicine study finds that melatonin usage may prevent COVID-19 infection, though large-scale trials are needed. Researcher Feixiong Cheng, PhD, discusses his team’s findings.
A new study led by researchers from Cleveland Clinic reports that receiving the influenza vaccine does not increase a person’s risk for contracting COVID-19 or worsen associated morbidity or mortality. Joe Zein, MD, a practicing pulmonologist in the Respiratory Institute, shares insights from the study.
A pacuity of models hinders the development of treatments for Ewing sarcoma, a common and deadly pediatric cancer involving bone and soft tissues. To remedy this, researchers are creating zebrafish models that will enable the study of the biology of Ewing sarcoma.
Traditional methods of drug discovery cannot keep up with the rapid emergence and mutation of human coronavirus epidemics. Feixiong Cheng, PhD, has applied a network-based prediction model to identify targets for drug repurposing for the treatment of COVID-19.